BPBrock Pluimer

Brock Pluimer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Brock Pluimer has a total of 47 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Electroacupuncture improves cognitive function and neuropsychiatric symptoms in breast cancer survivors: a pilot randomized controlled trial

    by Ding Quan Ng, Matthew Heshmatipour, Julia Trudeau, Apeksha Sridhar, Brock Pluimer, Olivia G G Drayson, Sayeh M Lavasani, Ritesh Parajuli, Sanghoon Lee, Anshu Agrawal, et al.

    Background: We conducted a randomized, double-blinded pilot trial to compare the impact of two electroacupuncture (EA) regimens on co-occurring neuropsychiatric symptoms among breast cancer survivors (BCS). Methods: BCS who self-reported cognitive impairment, fatigue, insomnia, or psychological distress were randomized (1:1) to receive ten weekly EA to target either neuropsychiatric-specific (nEA) or non-neuropsychiatric-specific (sEA) acupoints. Primary endpoints were the within-group pre-post effect sizes (Glass’s Δ) in symptom severities, adjusted for multiple comparisons (p-adjusted). Outcomes were assessed using neurocognitive tests (CANTAB®), PROs (FACT-Cog, MFSI-SF, EORTC QLQ-C30), plasma biomarkers, and neuroimaging. Responders were defined by reliable change index (for objective cognition) or MCID (for PROs). Results: Thirty-five were recruited, with 30 (86%) completing all sessions. The mean (±SD) age was 58.2 (±12.2) years, and 86% reported co-occurring symptoms. Following treatment, the nEA group demonstrated significant improvements in attention (T3: Δ = 0.562, T4: Δ = 0.708, both p-adjusted < 0.05) and distress (T3: Δ = 0.764, T4: Δ = 0.711, both p-adjusted < 0.05). More responders were observed after nEA treatment for objective cognition (42.9% vs 12.5%) and distress (50% vs 37.5%). nEA-treated participants showed increased gray matter volume compared to sEA (p = 0.033), which positively correlated with better attention function (r = 0.69, p = 0.020). nEA-related improvements in memory and response speed were associated with reduced connectivity in the Default Mode Network (DMN–SFG, r=-0.93, p < 0.01) and increased connectivity in the Dorsal Attention Network (DAN–SMG, r = 0.86, p < 0.001), respectively. All adverse events were grade 2 or lower. Conclusions: EA targeting neuropsychiatric-specific acupoints suggests improvements in cognition and distress symptoms in BCS, warranting validation in larger, multicenter trials. Clinicaltrials.gov: NCT05283577.


  • Open Access

    A proof-of-concept study on the use of large language models for assessing research methodology in neuroimaging

    by Brock Pluimer, Apeksha Sridhar, Ishtiaq Mawla, Helen Mengxuan Wu, Roshni Lulla, Sarah Hennessy, Patrick Sadil, Rishab Iyer, Eric Ichesco, Anson Kairys, et al.

  • Preventing antisocial robots: A pathway to artificial empathy

    by Leonardo Christov-Moore, Nicco Reggente, Anthony Vaccaro, Felix Schoeller, Brock Pluimer, Pamela K. Douglas, Marco Iacoboni, Kingson Man, Antonio Damasio, Jonas T. Kaplan

    Given the accelerating powers of artificial intelligence (AI), we must equip artificial agents and robots with empathy to prevent harmful and irreversible decisions. Current approaches to artificial empathy focus on its cognitive or performative processes, overlooking affect, and thus promote sociopathic behaviors. Artificially vulnerable, fully empathic AI is necessary to prevent sociopathic robots and protect human welfare.


  • Open Access

    Top2a promotes the development of social behavior via PRC2 and H3K27me3

    by Yijie Geng, Tejia Zhang, Ivy G. Alonzo, Sean C. Godar, Christopher Yates, Brock R. Pluimer, Devin L. Harrison, Anjali K. Nath, Jing-Ruey Joanna Yeh, Iain A. Drummond, et al.

    Little is understood about the embryonic development of sociality. We screened 1120 known drugs and found that embryonic inhibition of topoisomerase IIα (Top2a) resulted in lasting social deficits in zebrafish. In mice, prenatal Top2 inhibition caused defects in social interaction and communication, which are behaviors that relate to core symptoms of autism. Mutation of Top2a in zebrafish caused down-regulation of a set of genes highly enriched for genes associated with autism in humans. Both the Top2a-regulated and autism-associated gene sets have binding sites for polycomb repressive complex 2 (PRC2), a regulatory complex responsible for H3K27 trimethylation (H3K27me3). Moreover, both gene sets are highly enriched for H3K27me3. Inhibition of the PRC2 component Ezh2 rescued social deficits caused by Top2 inhibition. Therefore, Top2a is a key component of an evolutionarily conserved pathway that promotes the development of social behavior through PRC2 and H3K27me3.